Rabiya S Tuma. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Administration, OralAntineoplastic Agents/administration & dosageAntineoplastic Agents/bloodAntineoplastic Agents/pharmacokineticsBenzamidesBiological AvailabilityDasatinibDisease ProgressionDrug Administration ScheduleDrug InteractionsDrug Resistance, NeoplasmGastrointestinal Stromal Tumors/bloodGastrointestinal Stromal Tumors/drug therapyHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL Positive/bloodLeukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapyNeoplasms/bloodNeoplasms/drug therapyPatient CompliancePiperazines/administration & dosagePiperazines/bloodPiperazines/pharmacokineticsProtein Kinase Inhibitors/administration & dosageProtein Kinase Inhibitors/bloodPyrimidines/administration & dosagePyrimidines/bloodPyrimidines/pharmacokineticsThiazoles/administration & dosageThiazoles/blood
Substances： See more » Antineoplastic AgentsBenzamidesPiperazinesProtein Kinase InhibitorsPyrimidinesThiazolesImatinib MesylateDasatinib
Year: 2008 PMID： 18577740 DOI： 10.1093/jnci/djn230
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506